This is a phase II, study of BKM120 in patients with high-risk, localized prostate cancer.
Eligible patients will be enrolled and scheduled to have an ultrasound-guided biopsy of the
prostate to confirm high-risk disease and collect prostate tissue for analysis. Two weeks
after the biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at
this dose level orally once daily for 14 days prior to radical prostatectomy at University of
California, San Francisco. Radical prostatectomy will be performed on the day of the last
dose of BKM120 at day 14. No further drug will be tken after the radical prostatectomy.